Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
antibiotics
immune checkpoint inhibitors
lung cancer
microbiota
proton pump inhibitors
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
ISSN: 1569-8041
Titre abrégé: Ann Oncol
Pays: England
ID NLM: 9007735
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
30
07
2019
revised:
08
12
2019
accepted:
04
01
2020
pubmed:
3
3
2020
medline:
7
1
2021
entrez:
3
3
2020
Statut:
ppublish
Résumé
Preclinical data have shown that proton pump inhibitors (PPI) can modulate the microbiome, and single-arm studies suggested that antibiotics (ATB) may decrease the efficacy of immune checkpoint inhibitors (ICI), but randomized controlled trial data are lacking. This pooled analysis evaluated the effect of ATB and PPI on outcome in patients randomized between ICI and chemotherapy. This retrospective analysis used pooled data from the phase II POPLAR (NCT01903993) and phase III OAK (NCT02008227) trials, which included 1512 patients with previously treated non-small-cell lung cancer (NSCLC) randomly assigned to receive atezolizumab (n = 757) or docetaxel (n = 755). The main objective of this analysis was to assess the impact of ATB and PPI use on overall survival (OS) and progression-free survival (PFS). A total of 169 (22.3%) patients in the atezolizumab group and 202 (26.8%) in the docetaxel group received ATB, and 234 (30.9%) and 260 (34.4%), respectively, received PPI. Multivariate analysis in all patients revealed that ATB were associated with shorter OS [hazard ratio (HR) 1.20, 95% confidence interval (CI) 1.04-1.39], as was PPI (HR 1.26, 95% CI 1.10-1.44). Within the atezolizumab population, OS was significantly shorter in patients who received ATB (8.5 versus 14.1 months, HR 1.32, 95% CI 1.06-1.63, P = 0.01) or PPI (9.6 versus 14.5 months, HR 1.45, 95% CI 1.20-1.75, P = 0.0001). PPI use was associated with shorter PFS in the atezolizumab population (1.9 versus 2.8 months, HR 1.30, 95% CI 1.10-1.53, P = 0.001). There was no association between ATB and PPI use and PFS or OS within the docetaxel population. In this unplanned analysis from two randomized trials, data suggest that ATB or PPI use in patients with metastatic NSCLC is associated with poor outcome and may influence the efficacy of ICI.
Sections du résumé
BACKGROUND
Preclinical data have shown that proton pump inhibitors (PPI) can modulate the microbiome, and single-arm studies suggested that antibiotics (ATB) may decrease the efficacy of immune checkpoint inhibitors (ICI), but randomized controlled trial data are lacking. This pooled analysis evaluated the effect of ATB and PPI on outcome in patients randomized between ICI and chemotherapy.
PATIENTS AND METHODS
This retrospective analysis used pooled data from the phase II POPLAR (NCT01903993) and phase III OAK (NCT02008227) trials, which included 1512 patients with previously treated non-small-cell lung cancer (NSCLC) randomly assigned to receive atezolizumab (n = 757) or docetaxel (n = 755). The main objective of this analysis was to assess the impact of ATB and PPI use on overall survival (OS) and progression-free survival (PFS).
RESULTS
A total of 169 (22.3%) patients in the atezolizumab group and 202 (26.8%) in the docetaxel group received ATB, and 234 (30.9%) and 260 (34.4%), respectively, received PPI. Multivariate analysis in all patients revealed that ATB were associated with shorter OS [hazard ratio (HR) 1.20, 95% confidence interval (CI) 1.04-1.39], as was PPI (HR 1.26, 95% CI 1.10-1.44). Within the atezolizumab population, OS was significantly shorter in patients who received ATB (8.5 versus 14.1 months, HR 1.32, 95% CI 1.06-1.63, P = 0.01) or PPI (9.6 versus 14.5 months, HR 1.45, 95% CI 1.20-1.75, P = 0.0001). PPI use was associated with shorter PFS in the atezolizumab population (1.9 versus 2.8 months, HR 1.30, 95% CI 1.10-1.53, P = 0.001). There was no association between ATB and PPI use and PFS or OS within the docetaxel population.
CONCLUSION
In this unplanned analysis from two randomized trials, data suggest that ATB or PPI use in patients with metastatic NSCLC is associated with poor outcome and may influence the efficacy of ICI.
Identifiants
pubmed: 32115349
pii: S0923-7534(20)35927-5
doi: 10.1016/j.annonc.2020.01.006
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antibodies, Monoclonal, Humanized
0
Proton Pump Inhibitors
0
atezolizumab
52CMI0WC3Y
Banques de données
ClinicalTrials.gov
['NCT01903993', 'NCT02008227']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
525-531Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure MC reports grants to the institute from Bristol Myers Squibb/II-ON and Roche, outside the submitted work. AC and ADS are employees of F. Hoffmann-La Roche Ltd. DRN is an employee of Genentech Inc. and reports ownership of stocks from F. Hoffmann-La Roche Ltd. DRG reports a consulting or advisory role for AstraZeneca, Celgene, CellMax Life, Genentech, Guardant Health, Lilly, Liquid Genomics, Inc., and research funding from AstraZeneca/MedImmune (Inst) and Genentech (Inst). AR reports a consultant or advisory role for AbbVie, AstraZeneca/MedImmune, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, MSD, Pfizer, and Roche/Genentech. MLA is an employee of Genentech Inc. and is now an employee of Insitro. TP reports honoraria received from Novartis, BMS, Merck, Pfizer, Roche, and AstraZeneca. MK reports funding and a speaker's fee to the institute from BMS, Roche and an unpaid advisory role for BMS, outside the submitted work. FGH reports research funding from BMS, Accuray Inc., Bioprotect, and Prostate Cancer Foundation.